IMTX
Immatics N.V.stockNASDAQ
immatics is a clinical-stage biopharmaceutical company active in the discovery and development of t-cell redirecting immunotherapies for the treatment of cancer. our transformative product candidates are - best in class - adoptive cell therapies and bispecific tcr molecules. these products are directed against tumor targets that have been identified and validated by immatics' proprietary and world-leading xpresident® technology. our mission is to bring the power of t-cell redirecting immunotherapies to cancer patients. quick facts - 150 team members - >100 targets covering 20 major solid and liquid tumors - about 80% of discovered targets are novel - 2 proprietary technology platforms - 8 proprietary development programs, thereof 2 in the clinic in 2017 - multiple partnered programs - raised more than $230m in cash in five financings read more about immatics on our homepage: https://immatics.com/ find us on twitter and xing: twitter: http://bit.ly/2dfbpre xing: http://bit.ly/2e1kkpv l
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 6.52 | 2026-11-12 | -6.37% | 0.239 |
| 1M | 7.05 | 2026-10-19 | -13.40% | 1.663 |
| 3M | 9.25 | 2026-08-19 | -34.00% | 1.549 |
| 6M | 10.70 | 2026-05-19 | -42.94% | 1.228 |
| 1Y | 10.33 | 2025-11-19 | -40.90% | 1.456 |
| 2Y | 7.81 | 2024-11-19 | -21.83% | — |
| 5Y | 11.89 | 2021-11-19 | -48.65% | 1.050 |
Immatics N.V. (NASDAQ:IMTX) stock price today is $6.11, and today's volume is 1,571,188. IMTX is down 2.941% today. The 30 day average volume is 1.18M. IMTX market cap is $929.59M with 152.27M shares outstanding.